Low androgen/progesterone or high oestrogen/androgen receptors ratio in serous ovarian cancer predicts longer survival
-
Published:2024-09
Issue:3
Volume:24
Page:100917
-
ISSN:1642-431X
-
Container-title:Reproductive Biology
-
language:en
-
Short-container-title:Reproductive Biology
Author:
Gogola-Mruk Justyna,
Pietrus Miłosz,
Piechowicz Maryla,
Milian-Ciesielska KatarzynaORCID,
Głód Paulina,
Wolnicka-Glubisz AgnieszkaORCID,
Szpor JoannaORCID,
Ptak AnnaORCID
Reference50 articles.
1. Epithelial ovarian cancer: evolution of management in the era of precision medicine;Lheureux;CA Cancer J Clin,2019
2. PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer;González-Martín;N Engl J Med,2019
3. Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer;Moore;N Engl J Med,2018
4. Perren T.J., Swart A.M., Pfisterer J., Ledermann J.A., Pujade-Lauraine E., Kristensen G. et al. ; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484–96. doi: 10.1056/NEJMoa1103799. Erratum in: N Engl J Med. 2012 Jan 19;366(3):284. PMID: 22204725.
5. Ray-Coquard I. , Pautier P. , Pignata S. , Pérol D. , González-Martín A. , Berger R. et al. ; PAOLA-1 Investigators. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2416–2428. doi: 10.1056/NEJMoa1911361. PMID: 31851799.